SCHEMBL3002272

SCHEMBL3002272

O=S(=O)(c1ccccc1C(F)(F)F)N1CCN(c2nc(-c3ccc(F)c(F)c3)cs2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.59
MEN1 O00255 3/20 0.59
LMNA P02545 3/20 0.59
ALDH1A1 P00352 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
MAPT P10636 2/20 0.59
L3MBTL1 Q9Y468 1/20 0.53
MAPK1 P28482 3/20 0.49
USP2 O75604 1/20 0.49
RECQL P46063 1/20 0.49
HSD17B10 Q99714 1/20 0.49
GBA1 P04062 2/20 0.48
RAB9A P51151 1/20 0.45
ALOX5AP P20292 1/20 0.45
FEN1 P39748 1/20 0.45
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
ITGB2 P05107 1/20 0.44
ICAM1 P05362 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3652767 0.94 KMT2A (0.53) KMT2AMEN1LMNAALDH1A1SMN1; SMN2
SCHEMBL3006305 0.93 KMT2A (0.57) KMT2AMEN1LMNAALDH1A1SMN1; SMN2
SCHEMBL3017789 0.93 KMT2A (0.57) KMT2AMEN1LMNAALDH1A1SMN1; SMN2
SCHEMBL3015763 0.89 MEN1 (0.56) KMT2AMEN1LMNAALDH1A1SMN1; SMN2
SCHEMBL3014667 0.88 MAPT (0.61) KMT2AMEN1LMNAALDH1A1SMN1; SMN2
SCHEMBL3016160 0.88 KMT2A (0.61) KMT2AMEN1LMNAALDH1A1SMN1; SMN2
SCHEMBL3007681 0.88 LMNA (0.63) KMT2AMEN1LMNAALDH1A1SMN1; SMN2
SCHEMBL3010997 0.88 KMT2A (0.55) KMT2AMEN1LMNAALDH1A1SMN1; SMN2
SCHEMBL3011370 0.87 KMT2A (0.55) KMT2AMEN1LMNAALDH1A1SMN1; SMN2
SCHEMBL3007292 0.87 SMN1; SMN2 (0.62) KMT2AMEN1LMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885MEN1 454/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.